Linagliptin Stada (Linagliptin)

• Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.
• Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting glucose levels when used alone.
• Type 2 diabetes mellitus (combination with metformin): enhances overall glycemic control by adding a complementary mechanism.
• Type 2 diabetes mellitus (adjunct to diet and exercise): supports blood sugar regulation as part of comprehensive lifestyle management.

• Linagliptin selectively and reversibly inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4). By blocking DPP‑4, it prevents rapid degradation of incretin hormones such as GLP‑1 and GIP, leading to increased insulin secretion from pancreatic β‑cells and reduced glucagon release from α‑cells in a glucose‑dependent manner, thereby improving both post‑prandial and overall glycemic control.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient head pain.
• Dizziness: sensation of light‑headedness.
• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe allergic reactions: rash, angioedema or anaphylaxis.
• Bullous pemphigoid or Stevens‑Johnson syndrome: serious skin disorders requiring immediate medical attention.

• When prescribing Linagliptin, clinicians should consider several safety aspects to minimize risk.
• Renal impairment: monitor renal function, although dose adjustment is not routinely required.
• Hepatic impairment: use with caution and observe liver enzymes.
• Cardiovascular disease: assess for any history of heart failure or ischemic events.
• Pregnancy and lactation: safety has not been established; avoid use unless benefits outweigh risks.
• Elderly patients: watch for hypoglycemia, especially when combined with insulin or sulfonylureas.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with insulin or sulfonylureas: may cause severe hypoglycemia.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can reduce linagliptin exposure and diminish glucose‑lowering effect.
• Combination with other DPP‑4 inhibitors: additive effect increases risk of adverse events.

Moderate Interactions (Monitor Closely)

• Diuretics (thiazides, loop diuretics): may enhance the risk of dehydration and affect blood glucose.
• ACE inhibitors or ARBs: monitor blood pressure and renal function.
• NSAIDs: observe for potential renal function changes.
• Anticoagulants (warfarin): watch for altered INR values.